| |
Whats More Dangerous, Your Aspirin Or Your Car? Thinking Rationally About Drug Risks (And Benefits)
Joshua T. Cohen and
Peter J. Neumann
We compare mortality risks of several common drugs with risks related to work, transportation, and recreation. Comparing risks can provide a more intuitive sense of the magnitude of drug risks than stand-alone estimates can, to help inform policy discussions. The drug risks we quantify generally exceed the magnitude of risks for other domains (although aspirin and cars are similarly "risky" under the definition of risk used here). Nonetheless, these comparisons underscore a crucial point: that risks should not be evaluated without considering attendant benefits. We discuss the need for the Food and Drug Administration to compare risks and benefits quantitatively, consistently, and explicitly.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. L. Nelson, J. T. Cohen, D. Greenberg, and D. M. Kent
Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation
Ann Intern Med,
November 3, 2009;
151(9):
662 - 667.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Comments:
Read all Comments
- Facts on Tysabri
- David E. Kaplan
- Health Affairs, 9 May 2007
[Full text]
- Response To Tysabri Critique
- Joshua T. Cohen, et al.
- Health Affairs, 9 May 2007
[Full text]
- Majority of the MS Community's Views on Tysabri
- Lauren M. Roberts
- Health Affairs, 10 May 2007
[Full text]
- Valuable Statistics
- Andrew H. White
- Health Affairs, 14 May 2007
[Full text]
- An Opportunity For Clarity
- Harold Katlin
- Health Affairs, 10 May 2007
[Full text]
- Risks And Benefits Of Tysabri
- Joshua T. Cohen, et al.
- Health Affairs, 10 May 2007
[Full text]
- Tysabri Reference In The Cohen/Neumann Paper
- Chris Chan
- Health Affairs, 10 May 2007
[Full text]
- Root-Cause Failure Analysis Of Drug-Induced PML Morbidity
- Mike Barron
- Health Affairs, 14 May 2007
[Full text]
|